Atlas market file · Equity · United States
Alpha Cognition Inc.ACOG
- Last close
- 8.67
- Change
- +1.76%
- 96-bar range
- 4.87 – 9.27
- As of
- 6 Aug 2026
Alpha Cognition Inc. is a biological products, (no diagnostic substances) issuer listed as ACOG on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
ACOG
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 92 weekly closes (+61.45% over the window).
Source rail: Yahoo Finance chart API (ACOG). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for ACOG. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
ACOG public profile
Biological products, (no diagnostic substances) issuer. Alpha Cognition Inc. is connected to current market context, cited company sources and its retained research file.
Alpha Cognition Inc. trades as ACOG on NASDAQ. Alpha Cognition Inc. (ACOG) has a latest verified close of 8.67, up 1.76%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files ACOG under USA Stocks for browsing.
What changed for Alpha Cognition Inc. today
Alpha Cognition Inc. (ACOG) reported $3.5M in revenue and a $6.5M net loss for the quarter ending March 31, 2026, per its latest 10-Q filing. Despite holding $54.2M in cash, the company burned through $11.8M in operating cash, raising questions about its ability to commercialize ZUNVEYL, its FDA-approved Alzheimer’s treatment.
ACOG’s core business revolves around developing therapies for neurodegenerative diseases, with ZUNVEYL as its flagship product. However, the company’s inventory increased to $6.0M, a $920,218 rise, despite minimal revenue-a disconnect that suggests either overproduction or sluggish sales in its target markets.
Recent filings highlight insider transactions, including shares sold by executives, even as the board added Dr. Robert Wills as Chairman. Wills’ background includes managing $1B+ in revenue at Biogen, a stark contrast to ACOG’s current financial struggles. The company also announced participation in a B. Riley securities summit, aiming to boost investor confidence.
Chart-wise, ACOG’s liquidity remains a concern, with 21.9M diluted shares outstanding and no buyback program disclosed. The lack of cash flow from operations (-$11.8M) could pressure the stock if near-term catalysts fail to materialize.
Risks include sustained cash burn, inventory buildup, and reliance on a single product. Catalysts involve international licensing deals, clinical trial updates, and potential board-driven strategy shifts. The source directs readers to the company’s next earnings report for guidance on cash runway and ZUNVEYL’s commercial progress.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
ACOG technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on ACOG
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep ACOG research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
ACOG FAQ
What is Alpha Cognition Inc. (ACOG)?Alpha Cognition Inc. (ACOG) has a latest verified close of 8.67, up 1.76%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed...
Alpha Cognition Inc. (ACOG) has a latest verified close of 8.67, up 1.76%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for ACOG?Alpha Cognition Inc. (ACOG) has a latest verified close of 8.67, up 1.76%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks...
Alpha Cognition Inc. (ACOG) has a latest verified close of 8.67, up 1.76%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files ACOG under USA Stocks for browsing.
How often is the ACOG page updated?The ACOG public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The ACOG public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for ACOG?The ACOG file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:ACOG. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The ACOG file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:ACOG. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on ACOG?Yes. The workstation can open ACOG, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open ACOG, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this ACOG page investment advice?No. The ACOG page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The ACOG page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →